Male sex and high HBV DNA were associated with increased flare risk in this single-center, randomized phase IV study.
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.
Obeticholic acid showed significant, dose-dependent improvement in the primary endpoint of fibrosis improvement with no worsening of NASH in this interim analysis of a large randomized trial.
Although this trial did not meet the primary endpoint of decreasing mean hepatic venous pressure gradient in patients with NASH cirrhosis and severe portal hypertension, positive signals were seen that support additional exploration of emricasan in patients with severe portal hypertension.
Reduced risk of HCC with TDF vs ETV maintained in propensity score–weighted analysis of Hong Kong cohort including more than 29,000 patients with CHB.
Large observational study reported variations in DAA efficacy among patients with genotype 3 HCV and compensated cirrhosis.
Large database study finds significant gaps remain across all stages of the HCV care cascade in US.
This pilot study conducted in a rural Egyptian village established the feasibility of a simplified, same-day, test-and-treat program for HCV and HBV infection.
High uptake of HCV testing and treatment noted in this observational cohort study, although female sex and not currently receiving OST were each associated with reduced treatment uptake.
Simplified monitoring schedule resulted in similar safety and efficacy but was not noninferior to standard monitoring for SVR12 in ITT population.